Motorola has accused rival Hytera Communications of a “deliberate strategy” of filing late affidavits to throw Motorola off in an already highly contentious patent and copyright case over digital radio devices.
A judge has panned evidence put on by Fuchs Lubricants in a patent dispute with Quaker Chemical as “woefully inadequate” and “absolutely garbage”, partially shooting down the firm’s attempt to block discovery of allegedly privileged documents.
A judge that rejected a bid by Sanofi-Aventis for an injunction blocking rival Alphapharm from listing an insulin injector pen on the PBS erred in his consideration of the harm it would face, the drug giant has told the Full Federal Court.
Hytera Communications has been ordered to hand over source code that Motorola Solutions claims was stolen by three employees who jumped ship between the companies.
Hytera Communications has won its bid to have a new copyright case brought against it by rival Motorola Solutions heard separately from a patent infringement trial scheduled to begin in July next year.
Rokt has won its bid to patent a digital advertising system, the first major court victory in one of three challenges to IP Australia’s stance on the patentability of computer software.
Motorola Solutions wants to amend its pleadings in an ongoing patent case against Shenzen-based Hytera Communications to add copyright claims relating to the source code for the radio devices at the centre of the dispute.
A software-implemented business method could be patentable if programmed into a computer with “some ingenuity”, IP Australia told the Full Federal Court as a landmark appeal between rival tech companies Encompass and Infotrack wrapped up Friday.
Generic drug maker Alphapharm says rival Sanofi-Aventis waited to amend its injector pen patent until the heated IP battle between the two firms had commenced, despite knowing about the amendments for three years.
Generic drug maker Alphapharm has lost another bid for documents from Sanofi-Aventis in advance of a hearing on Sanofi’s interlocutory application seeking to block the generic drug maker from listing its injector pen on the Pharmaceutical Benefits Scheme.